OUR STORIES Follow @PolypeptideG 11 May 2021 Proclamation honoring Jane Salik upon her retirement The city of Torrance, California, honored Jane Salik for her investment in the Torrance community and her outstanding contributions to the Science and Peptide Industry. 05-11-21 - Proclamation Jane Salik retirement 29 Apr 2021 Stock Exchange Listing What an exhilarating day! Today the PolyPeptide Group became a public company. Our shares began trading on SIX, the Swiss Stock Exchange. Our entire Executive Committee was there to mark the occasion, including our outgoing CEO Jane Salik and our new CEO Raymond De Vre. See additional information on our new Investors section 28 Jan 2021 PolyPeptide News Flash, #1, 2021 PolyPeptide Group maintained a strong and healthy pipeline that has gained a significant growth in 2020. This growth in Pipeline Projects reflects the growth in peptide therapeutics market and emphasizes the importance of peptides in drug and vaccine development. Also in this Newsletter "New In-Silico Development Tools Support More Efficient Process Design" and get to know Christelle Bobier, Director Global Engineering and Manufacturing Technology read more 17 Sep 2020 PolyPeptide News Flash, #3, 2020 As a Global Leader in Peptide Manufacturing and Development, the PolyPeptide Group has been actively engaged on projects with clients who are developing peptide-based therapies and vaccines to combat COVID-19. Also in this News Flash, learn more about PolyPeptide's recent capacity expansion through investment and innovation. read more 04 Jun 2020 Press Release: PolyPeptide Group Selected by Novavax to Manufacture Critical Intermediates of Matrix-M™ Adjuvant for its COVID-19 Vaccine The PolyPeptide Group, a global Contract Development and Manufacturing Organization (CDMO) for Peptide, Peptidomimetic and other Drug Substances, has announced that it has partnered with Novavax Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax’ novel coronavirus vaccine candidate, NVX-CoV2373. PolyPeptide Group will produce two key intermediates used in the production of Matrix-M™, the adjuvant component of the vaccine, which is being used to enhance the vaccine’s immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 is a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology. Read the press release 12 May 2020 PolyPeptide News Flash, #2, 2020 While the COVID-19 crisis continues, the PolyPeptide Group is actively engaged in helping find treatments and vaccines for COVID-19. See report on promising therapies in our latest Newsletter. We are also highlighting our ongoing Digitalization projects as well as introducing our new Global Director for Quality Control and Analytical Development, Eran Benjamin, read more 23 Apr 2020 Information Letter on COVID-19 Download letter PDF here Dear Valued Customer, While the COVID-19 crisis continues, I want to assure you that the PolyPeptide Group remains ready to support your business. Our sites are operating at almost-full capacity. At the same time, we have put numerous steps in place to protect the health and safety of our employees, including rigorous cleaning and infection control procedures. Our company is also actively engaged in helping to find treatments and cures for COVID-19. Within the next few weeks, we will have teams at almost all sites working on projects to: Develop a peptide-based vaccine or vaccine cocktail against the virus Use peptides as immuno-modulators to allow our own immune system to fight this disease Use anti-inflammatory peptides to fight the excessive release of cytokines that this disease may cause Develop entry-inhibiting peptides that may inhibit coronavirus’ ability to enter human lung cells We would be honored to help further your projects to combat the virus. Our lines of communication remain open as we work to support your projects, your business, and your patients. Thank you for your ongoing partnership during this challenging time. Wishing you and your family good health, Kind regards, Jane Salik, CEO Download letter PDF here 24 Feb 2020 New member of the Medicon Valley Alliance We are happy to inform that the PolyPeptide Group is from now a member of the Medicon Valley Alliance (MVA). It is a non-profit membership organization, the leading life science cluster in Scandinavia and one of the largest in Europe. With this membership, we wish to strengthen our presence, support and knowledge sharing in the region as the global leader in Peptide Development and Manufacturing. OUR STORIES Our Stories Corporate News Articles Publications & Posters Upcoming events Sign up for PolyPeptide’s Newsletter Email* Last Name and First Name Company Country Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo, Democratic Republic of the Congo, Republic of the Cook Islands Costa Rica Croatia Cuba Curaçao Cyprus Czech Republic Côte d'Ivoire Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Eswatini (Swaziland) Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea Northern Mariana Islands Norway Oman Pakistan Palau Palestine, State of Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Romania Russia Rwanda Réunion Saint Barthélemy Saint Helena Saint Kitts and Nevis Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu US Minor Outlying Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela Vietnam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Åland Islands GDPR Yes, I would like to receive the Polypeptide Brief as well as marketing communications regarding Polypeptide products, services, and events. I can unsubscribe at any time. The information collected from this form is recorded and transmitted to the staff of our company responsible for processing your message. See our privacy policy You have a right of access, rectification and opposition to the data concerning you, which you can exercise by going to this page: Contact the Personal Data Protection Officer CONTACT US UPCOMING EVENTS ABOUT US POLYPEPTIDE GROUP INFO INVESTORS CORPORATE NEWS OUR STORIES ABOUT US MEDIA CONTACT CONTACT US QUOTATION REQUEST CAREERS SOCIALS LINKEDIN FACEBOOK TWITTER YOUTUBE © Confidentiality 2021 PolyPeptide Group • Cookie management • Personal data • Sitemap ACTH (1-39) PorcineAtosibanCalcitoninCarbetocinDeslorelinDesmopressinExenatideFelypressinLeuprolideLiraglutideOctreotidePTH (1-34) TeriparatideSemaglutideSomatostatinTriptorelinVasopressin, 8-L-Arginine By clicking “Accept”, you consent to the use of ALL the cookies on our website . However you may visit Cookie Settings to provide a controlled consent. Cookie settingsACCEPT